Molecular-genetic testing in preoperative diagnosis and choice of surgical tactics in patients with thyroid neoplasms

Abstract

The high frequency of the detection of follicular thyroid tumors requires the development of the most effective new methods for their differential diagnosis to early verification of well-differentiated cancer, reduce the number of unjustified surgical interventions, select their rational volume, and improve the treatment results. The use of molecular genetic research methods in preoperative diagnostics and the choice of surgical tactics in patients with the thyroid neoplasms was substantiated. To optimize the algorithm of diagnosis and treatment, a retrospective analysis of the results of examination and surgical treatment of 100 patients with the thyroid neoplasms was carried out, the diagnosis of which was supplemented by the determination of molecular genetic markers in the cellular material of the puncture fine-needle biopsy using a flow fluor-cytometry and polymerase chain reaction. The diagnostic significance of the preoperative determination of the tumor marker Galectin-3, the V600E mutation of the BRAF gene in the puncture material in the detection of thyroid cancer and the choice of the rational surgical tactics was assessed. The prognostic value of the sodium iodide symporter in the development of a thyroid cancer resistance to postoperative radioactive iodine therapy has been established, which makes it possible to substantiate the need to expand the scope of the surgical intervention. The use of an optimized diagnostic and treatment algorithm, considering a new molecular genetic research methods in this category of the patients, contributes to the choice of individualized surgical tactics, depending on the nature of the pathological process.

Keywords

thyroid surgery / differential diagnosis / thyroid nodules / thyroid cancer / follicular neoplasms / algorithm of diagnosis and treatment / molecular genetic panel

References

[1] Maistrenko NA, Romashchenko PN, Krivolapov DS. Modern approaches to the diagnosis and surgical treatment of thyroid disorders. Military Medical Journal. 2018;339(1):37–46. (In Russ.).

[2] Майстренко Н.А., Ромащенко П.Н., Криволапов Д.С. Современные подходы к диагностике и хирургическому лечению заболеваний щитовидной железы // Военно-медицинский журнал. 2018. Т. 339, № 1. С. 37–46.

[3] Romashchenko PN, Maistrenko NA, Krivolapov DS, et al. Modern diagnostic and minimally invasive technology in thyroid surgery. Bulletin of the Russian Military Medical Academy. 2019;(S1): 101–105. (In Russ.).

[4] Ромащенко П.Н., Майстренко Н.А., Криволапов Д.С., и др. Современные диагностические и малоинвазивные технологии в хирургии щитовидной железы // Вестник Российской военно-медицинской академии. 2019. № S1. C. 101–105.

[5] Reshetova ON, Ivantsova AA, Mokeev AG. Fine-needle aspiration biopsy and liquid-based cytology of the nodular goiter: diagnostic value and analysis of the results. Bulletin of the Medical University Reaviz. 2019;(3):131–136. (In Russ.).

[6] Решетова О.Н., Иванцова А.А., Мокеев А.Г. Тонкоигольная аспирационная биопсия узлового зоба с применением метода жидкостной цитологии: диагностическая значимость, анализ полученных результатов // Вестник медицинского института РЕАВИЗ. 2019. № 3. С. 131–136.

[7] Sanabria A, Kowalski LP, Shah JP, et al. Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. Head Neck. 2017;40(4):855–866. DOI: 10.1002/hed.25029

[8] Sanabria A., Kowalski L.P., Shah J.P., et al. Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis // Head Neck. 2017. Vol. 40, No. 4. P. 855–866. DOI: 10.1002/hed.25029

[9] Lukyanov SA, Sergiyko SV, Titov SE, et al. Prospects of molecular genetic panels use in the preoperative differential diagnosis of nodular lesions of the thyroid gland. Surgery News. 2020;28(3): 284–289 (In Russ.) DOI: 10.18484/2305-0047.2020.2.284

[10] Лукьянов С.А., Сергийко С.В., Титов С.Е., и др. Перспективы использования молекулярно-генетических панелей в дооперационной дифференциальной диагностике узловых образований щитовидной железы // Новости хирургии. 2020. Т. 28, № 3. С. 284–289. DOI: 10.18484/2305-0047.2020.2.284

[11] Tavares C, Coelho MJ, Eloy C, et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Сonnect. 2018;7(1):78–90. DOI: 10.1530/EC-17-0302

[12] Tavares C., Coelho M.J., Eloy C., et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features // Endocr Сonnect. 2018. Vol. 7, No. 1. P. 78–90. DOI: 10.1530/EC-17-0302

[13] Vuong HG, Altibi AM, Duong UN, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol (Oxf). 2017;87(5): 411–417. DOI: 10.1111/cen.13413

[14] Vuong H.G., Altibi A.M., Duong U.N., et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis // Clin Endocrinol (Oxf). 2017. Vol. 87, No. 5. P. 411–417. DOI: 10.1111/cen.13413

[15] Yip L, Sosa JA. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment. JAMA Surg. 2016;151(7):663–670. DOI: 10.1001/jamasurg.2016.0825

[16] Yip L., Sosa J.A. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment // JAMA Surg. 2016. Vol. 151, No. 7. P. 663–670. DOI: 10.1001/jamasurg.2016.0825

[17] Romashchenko PN, Krivolapov DS, Simonova MS Significance of preoperative determination of the expression of sodium-iodide symporter in the selection of volume surgical intervention and forecast the efficiency of radioiodine therapy in patients with highly differentiated thyroid cancer. Science of Europe. 2021;2(67):62–67. (In Russ.). DOI: 10.24412/3162-2364-2021-67-2-62-67

[18] Ромащенко П.Н., Криволапов Д.С., Симонова М.С. Значимость дооперационного определения экспрессии натрий-йодидного симпортера в выборе объема оперативного вмешательства и прогнозе эффективности радиойодтерапии у больных высокодифференцированным раком щитовидной железы // Science of Europe. 2021. Т. 2, № 67. С. 62–67. DOI: 10.24412/3162-2364-2021-67-2-62-67

[19] Romashchenko PN, Krivolapov DS, Simonova MS Galectin-3 in preoperative diagnostics and selection of surgical tactics in patients with thyroid neoplasms. The Scientific Heritage. 2021;2(64):42–46. (In Russ.). DOI: 10.24412/9215-0365-2021-64-2-42-46

[20] Ромащенко П.Н., Криволапов Д.С., Симонова М.С. Galectin-3 в дооперационной диагностике и выборе хирургической тактики у больных новообразованиями щитовидной железы // The Scientific Heritage. 2021. Т. 2, № 64. С. 42–46. DOI: 10.24412/9215-0365-2021-64-2-42-46

[21] Simonova MS, Krivolapov DS. The role of molecular and genetic markers in preoperative diagnosis and choice of surgical tactics in patients with follicular neoplasia and differentiated thyroid cancer. Izvestia of the Russian Military Medical Academy. 2021; 40(S1–3):292–296 (In Russ.).

[22] Симонова М.С., Криволапов Д.С. Роль молекулярно-генетических маркеров в дооперационной диагностике и выборе хирургической тактики у больных фолликулярными неоплазиями и высокодифференцированным раком щитовидной железы // Известия Российской военно-медицинской академии. 2021. Т. 40, № S1–3. С. 292–296.

[23] Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;11(27):1341–1346. DOI: 10.1089/thy.2017.0500

[24] Cibas E.S., Ali S.Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology // Thyroid. 2017. Vol. 11, No. 27. P. 1341–1346. DOI: 10.1089/thy.2017.0500

RIGHTS & PERMISSIONS

Romashchenko P.N., Maistrenko N.A., Ivanov A.M., Krivolapov D.S., Simonova M.S.